arrow
C

Cristiano A. F. Zerbini

centro paulista de pesquisa investigacao clinica
H指数:47
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Management of osteoporosis in older men: a systematic review of randomized trials of pharmacological and non-pharmacological strategies

老年男性骨质疏松症的管理:对药物和非药物策略的随机试验的系统综述

2026-05-220
PRE
A new FRAX model for Brazil
2023-11-283
OAAI
Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update This manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation (IOF)
2022-11-0917
PRE
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
2022-05-19221
OAAI
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

相对于阿仑膦酸盐,Romosozumab可改善绝经后妇女的腰椎骨量和骨强度参数: 绝经后高危骨质疏松症妇女主动控制骨折研究 (ARCH) 的结果

2021-11-0148
OAAI
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
2021-07-2055
OAAI
Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study

在中度至重度活动性类风湿关节炎和对甲氨蝶呤治疗反应不足的患者中,baricitinib与安慰剂的随机,双盲,安慰剂对照的III期研究的患者报告结果: RA-BALANCE研究的结果

2021-04-204
OAAI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

BNT162b2 mRNA Covid-19疫苗的安全性和有效性

2020-12-311.1W
OAAI
Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate

长期使用或不使用甲氨蝶呤的Baricitinib治疗类风湿关节炎的疗效和安全性: Baricitinib单药治疗或从甲氨蝶呤单药治疗或Baricitinib加甲氨蝶呤转换后的经验

2020-07-2925
PREAI
Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension

Odanacatib对绝经后骨质疏松妇女骨结构和质量的影响: 来自3期长期Odanacatib骨折试验 (LOFT) 及其扩展的5年数据

2020-03-0219
OAAI
Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort (vol 38, pg 2737, 2019)

拉丁美洲早期类风湿关节炎缓解和低疾病活动的临床预测因子:GLADAR队列研究数据(第38卷,第2737页,2019年)

2019-10-012
PRE